Robyn Karnauskas
Stock Analyst at Truist Securities
(3.68)
# 1,186
Out of 4,479 analysts
147
Total ratings
46.15%
Success rate
6.9%
Average return
Main Sectors:
Top Industries:
32 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BMEA Biomea Fusion | Downgrades: Hold | n/a | $4.43 | - | 3 | Jun 11, 2024 | |
| BIIB Biogen | Maintains: Buy | $340 | $228.82 | +48.59% | 13 | May 16, 2024 | |
| CRIS Curis | Maintains: Buy | $26 | $6.25 | +316.00% | 2 | May 15, 2024 | |
| CHRS Coherus BioSciences | Maintains: Buy | $8 → $7 | $1.39 | +403.60% | 11 | May 13, 2024 | |
| MRK Merck & Co. | Maintains: Buy | $142 → $143 | $127.72 | +11.96% | 8 | Apr 26, 2024 | |
| AMGN Amgen | Reiterates: Buy | $320 | $310.77 | +2.97% | 7 | Apr 12, 2024 | |
| REGN Regeneron Pharmaceuticals | Maintains: Buy | $1,135 | $1,044.66 | +8.65% | 14 | Apr 3, 2024 | |
| OABI OmniAb | Maintains: Buy | $10 | $3.67 | +172.48% | 2 | Mar 26, 2024 | |
| ABSI Absci | Maintains: Buy | $9 | $2.97 | +203.03% | 4 | Mar 26, 2024 | |
| TRML Tourmaline Bio | Reiterates: Buy | $74 | $12.55 | +489.64% | 2 | Mar 25, 2024 | |
| ROIV Roivant Sciences | Reiterates: Buy | $23 | $10.56 | +117.80% | 5 | Mar 25, 2024 | |
| IMVT Immunovant | Reiterates: Buy | $48 | $26.52 | +81.00% | 5 | Mar 25, 2024 | |
| RCUS Arcus Biosciences | Reiterates: Buy | $50 | $14.65 | +241.30% | 5 | Mar 25, 2024 | |
| LLY Eli Lilly | Reiterates: Buy | $850 | $906.71 | -6.25% | 4 | Mar 22, 2024 | |
| GILD Gilead Sciences | Downgrades: Hold | $91 → $82 | $68.40 | +19.88% | 9 | Feb 22, 2024 | |
| ABBV AbbVie | Maintains: Buy | $180 → $195 | $165.96 | +17.50% | 7 | Feb 6, 2024 | |
| VRTX Vertex Pharmaceuticals | Maintains: Buy | $456 → $508 | $473.78 | +7.22% | 10 | Jan 31, 2024 | |
| PFE Pfizer | Maintains: Buy | $42 → $36 | $27.83 | +29.36% | 5 | Dec 14, 2023 | |
| BMY Bristol-Myers Squibb Company | Reiterates: Buy | $84 | $40.45 | +107.66% | 1 | Oct 6, 2023 | |
| PTCT PTC Therapeutics | Downgrades: Hold | $25 | $30.39 | -17.74% | 1 | Oct 6, 2023 | |
| BTAI BioXcel Therapeutics | Downgrades: Hold | n/a | $1.12 | - | 5 | Oct 5, 2023 | |
| BMRN BioMarin Pharmaceutical | Reiterates: Buy | $140 | $82.22 | +70.27% | 5 | Sep 25, 2023 | |
| NCNA NuCana | Reiterates: Buy | $150 | $2.57 | +5,736.58% | 2 | Sep 6, 2023 | |
| FATE Fate Therapeutics | Reiterates: Hold | $7 | $3.22 | +117.39% | 3 | Aug 16, 2023 | |
| QURE uniQure | Maintains: Buy | $65 → $55 | $4.01 | +1,271.57% | 1 | May 11, 2023 | |
| MEIP MEI Pharma | Downgrades: Hold | n/a | $2.80 | - | 3 | Dec 6, 2022 | |
| ABCL AbCellera Biologics | Initiates: Buy | $29 | $2.77 | +946.93% | 1 | Nov 16, 2022 | |
| TIL Instil Bio | Maintains: Buy | $500 → $320 | $10.04 | +3,087.25% | 2 | Aug 23, 2022 | |
| KOD Kodiak Sciences | Maintains: Buy | $10 → $15 | $2.24 | +569.64% | 3 | Aug 9, 2022 | |
| OPT Opthea | Initiates: Buy | n/a | $1.93 | - | 1 | Nov 11, 2020 | |
| APLT Applied Therapeutics | Initiates: Buy | n/a | $4.35 | - | 1 | Oct 8, 2020 | |
| CALA Calithera Biosciences | Upgrades: Buy | n/a | $0.01 | - | 2 | Feb 16, 2018 |
Biomea Fusion
Jun 11, 2024
Downgrades: Hold
Price Target: n/a
Current: $4.43
Upside: -
Biogen
May 16, 2024
Maintains: Buy
Price Target: $340
Current: $228.82
Upside: +48.59%
Curis
May 15, 2024
Maintains: Buy
Price Target: $26
Current: $6.25
Upside: +316.00%
Coherus BioSciences
May 13, 2024
Maintains: Buy
Price Target: $8 → $7
Current: $1.39
Upside: +403.60%
Merck & Co.
Apr 26, 2024
Maintains: Buy
Price Target: $142 → $143
Current: $127.72
Upside: +11.96%
Amgen
Apr 12, 2024
Reiterates: Buy
Price Target: $320
Current: $310.77
Upside: +2.97%
Regeneron Pharmaceuticals
Apr 3, 2024
Maintains: Buy
Price Target: $1,135
Current: $1,044.66
Upside: +8.65%
OmniAb
Mar 26, 2024
Maintains: Buy
Price Target: $10
Current: $3.67
Upside: +172.48%
Absci
Mar 26, 2024
Maintains: Buy
Price Target: $9
Current: $2.97
Upside: +203.03%
Tourmaline Bio
Mar 25, 2024
Reiterates: Buy
Price Target: $74
Current: $12.55
Upside: +489.64%
Roivant Sciences
Mar 25, 2024
Reiterates: Buy
Price Target: $23
Current: $10.56
Upside: +117.80%
Immunovant
Mar 25, 2024
Reiterates: Buy
Price Target: $48
Current: $26.52
Upside: +81.00%
Arcus Biosciences
Mar 25, 2024
Reiterates: Buy
Price Target: $50
Current: $14.65
Upside: +241.30%
Eli Lilly
Mar 22, 2024
Reiterates: Buy
Price Target: $850
Current: $906.71
Upside: -6.25%
Gilead Sciences
Feb 22, 2024
Downgrades: Hold
Price Target: $91 → $82
Current: $68.40
Upside: +19.88%
AbbVie
Feb 6, 2024
Maintains: Buy
Price Target: $180 → $195
Current: $165.96
Upside: +17.50%
Vertex Pharmaceuticals
Jan 31, 2024
Maintains: Buy
Price Target: $456 → $508
Current: $473.78
Upside: +7.22%
Pfizer
Dec 14, 2023
Maintains: Buy
Price Target: $42 → $36
Current: $27.83
Upside: +29.36%
Bristol-Myers Squibb Company
Oct 6, 2023
Reiterates: Buy
Price Target: $84
Current: $40.45
Upside: +107.66%
PTC Therapeutics
Oct 6, 2023
Downgrades: Hold
Price Target: $25
Current: $30.39
Upside: -17.74%
BioXcel Therapeutics
Oct 5, 2023
Downgrades: Hold
Price Target: n/a
Current: $1.12
Upside: -
BioMarin Pharmaceutical
Sep 25, 2023
Reiterates: Buy
Price Target: $140
Current: $82.22
Upside: +70.27%
NuCana
Sep 6, 2023
Reiterates: Buy
Price Target: $150
Current: $2.57
Upside: +5,736.58%
Fate Therapeutics
Aug 16, 2023
Reiterates: Hold
Price Target: $7
Current: $3.22
Upside: +117.39%
uniQure
May 11, 2023
Maintains: Buy
Price Target: $65 → $55
Current: $4.01
Upside: +1,271.57%
MEI Pharma
Dec 6, 2022
Downgrades: Hold
Price Target: n/a
Current: $2.80
Upside: -
AbCellera Biologics
Nov 16, 2022
Initiates: Buy
Price Target: $29
Current: $2.77
Upside: +946.93%
Instil Bio
Aug 23, 2022
Maintains: Buy
Price Target: $500 → $320
Current: $10.04
Upside: +3,087.25%
Kodiak Sciences
Aug 9, 2022
Maintains: Buy
Price Target: $10 → $15
Current: $2.24
Upside: +569.64%
Opthea
Nov 11, 2020
Initiates: Buy
Price Target: n/a
Current: $1.93
Upside: -
Applied Therapeutics
Oct 8, 2020
Initiates: Buy
Price Target: n/a
Current: $4.35
Upside: -
Calithera Biosciences
Feb 16, 2018
Upgrades: Buy
Price Target: n/a
Current: $0.01
Upside: -